Latest On Sesen Bio, Inc (SESN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-08 04:52 EST | Dividend | A dividend of $0.36 has been announced on Mar 2, 2023. It will be paid Mar 8, 2023 with an ex-dividend date of Mar 8, 2023. | Neutral |  |
| 2023-03-06 04:52 EST | Dividend | A dividend of $0.36 has been announced on Mar 2, 2023. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 6, 2023. | Neutral | |
| 2023-03-02 21:43 EST | News | Sesen Bio wins shareholder approval for Carisma merger | N/A | |
| 2023-03-02 21:43 EST | News | Sesen Bio (SESN) Investor Presentation - Slideshow | N/A | |
| 2023-03-02 21:43 EST | News | Sesen Bio stockholders approve 1-for-20 reverse stock split | N/A | |
About Sesen Bio, Inc (SESN):
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma o read more...f the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
General
- Name Sesen Bio, Inc
- Symbol SESN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 25
- Fiscal Year EndDecember
- IPO Date2014-02-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.sesenbio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 31.67
- Price/Book (Most Recent Quarter) 5.98
- Enterprise Value Revenue 40.23
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.28
- Next Year EPS Estimate $0.05
- Next Quarter EPS Estimate -$0.11
- Profit Margin -199%
- Operating Margin -287%
- Return on Assets -17%
- Revenue 11.24 million
- Earnings Per Share -$1.05
- Revenue Per Share $0.1
- Gross Profit -17955000
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 512.79 million
- EBITDA -33451000
- Analyst Target Price $7
- Book Value Per Share $0.17
Share Statistics
- Shares Outstanding 167.58 million
- Shares Float 167.48 million
- % Held by Insiders 6%
- % Held by Institutions 17.89%
- Shares Short 2.37 million
- Shares Short Prior Month 1.47 million
- Short Ratio 0.24
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 0.72
- 52 Week High $3.54
- 52 Week Low $0.45
- 50 Day Moving Average 2.58
- 200 Day Moving Average 1.62
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Sesen Bio, Inc (SESN) Dividend Calendar:
Sesen Bio, Inc (SESN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Sesen Bio, Inc (SESN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Sesen Bio, Inc (SESN) Chart:
Sesen Bio, Inc (SESN) News:
Below you will find a list of latest news for Sesen Bio, Inc (SESN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sesen Bio, Inc (SESN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest SESN Trades:
Sesen Bio, Inc (SESN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-30 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-10-30 | 8-K (Current report) | |
| 2020-10-26 | 8-K (Current report) | |
| 2020-10-19 | 8-K (Current report) | |
| 2020-10-13 | 8-K (Current report) | |
| 2020-10-06 | 8-K (Current report) | |
| 2020-09-30 | 8-K (Current report) | |
| 2020-09-28 | 8-K (Current report) | |
| 2020-09-15 | 8-K (Current report) | |
| 2020-08-24 | 8-K (Current report) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-07 | 8-K (Current report) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-03 | 8-K (Current report) | |
| 2020-07-31 | 8-K (Current report) | |
| 2020-07-06 | 8-K (Current report) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 8-K (Current report) | |